Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

April 30, 2014

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

Tablet, 400mg orally, twice daily

RADIATION

SIR-Spheres

one time treatment and capped at 3.0 Gbq

Trial Locations (5)

169608

Singapore General Hospital, Singapore

169610

National Cancer Centre, Singapore

Unknown

Yangon GI & Liver Centre, Yangon

Selayang Hospital, Kuala Selangor

Seoul National University Bundang Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

collaborator

Sirtex Medical

INDUSTRY

lead

Singapore Clinical Research Institute

OTHER